glp 1 kidney protection Glucagon-like peptide 1(GLP-1) receptor agonists in the management of the patient with type 2diabetes mellitus and chronic disease: an approach for the nephrologist Real-World Evidence for GLP-1 Receptor
Description
It includes an increasing aging population and a growing prevalence of lifestyle diseases such as diabetes and obesity
Why GLP-1 Agonists May Increase Kidney Stone Risk The primary mechanism linking GLP-1 agonists to kidney stones is dehydration
Serious adverse events occur in less than 5% of patients in real-world studies
There are two FDA-approved versions of liraglutide, both of which are injections: Saxenda: FDA-approved for weight loss
